Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Beam Therapeutics Inc shares valued at $46,614 were purchased by CHRISTINE BELLON on Jan 22 ’26. At $34.00 per share, CHRISTINE BELLON acquired 1,371 shares.
Also, Cavanagh Bethany J sold 3,034 shares, netting a total of over 91,384 in proceeds. Following the sale of shares at $30.12 each, the insider now holds 41,011 shares.
Before that, Bellon Christine had sold 18,629 shares from its account. In a trade valued at $644,832, the Chief Legal Officer traded Beam Therapeutics Inc shares for $34.61 each. Upon closing the transaction, the insider’s holdings decreased to 18,629 shares, worth approximately $3.32 million.
As published in their initiating research note from Jefferies on October 09, 2025, Beam Therapeutics Inc [BEAM] has been a Buy and the price target has been revised to $41. Analysts at BofA Securities upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late March. As of March 10, 2025, Scotiabank has increased its “Sector perform” rating to a “Sector outperform” for BEAM. Earlier on January 29, 2025, Cantor Fitzgerald upgraded its rating. Their new recommendation was “an Overweight” for BEAM stock which previously was a “a Neutral”.
Analyzing BEAM Stock Performance
On last trading session, Beam Therapeutics Inc [NASDAQ: BEAM] rose 10.09% to $34.26. The stock’s lowest price that day was $30.9165, but it reached a high of $35.3399 in the same session. During the last five days, there has been a drop of approximately -3.25%. Over the course of the year, Beam Therapeutics Inc shares have jumped approximately 39.67%.
Is Beam Therapeutics Inc subject to short interest?
Stocks of Beam Therapeutics Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.66 million shares to 20.3 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 20.95 million shares. A decline of -3.23% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 12.93 of the overall float, the days-to-cover ratio (short ratio) decline to 12.93.
Which companies own the most shares of Beam Therapeutics Inc (BEAM)?
In terms of Beam Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 41 in the next 12 months, up nearly 31.75% from the previous closing price of $31.12. Analysts anticipate Beam Therapeutics Inc stock to reach 41 by 2026, with the lowest price target being 28. In spite of this, 6 analysts ranked Beam Therapeutics Inc stock as Buy at the end of 2026. On November 06, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and upgraded coverage with a $39.
